Q-omics provides the consensus-scored CD226 profile across patient tissues and cancer cell-line models. CD226 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD226 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CD226 RNA expression shows 17,877 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where CD226 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD226 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD226 survival associations across molecular data types. CD226 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD226 RNA expression–survival associations across cancer types. High CD226 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, UCEC, BRCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD226 RNA expression.
This table summarizes CD226 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CD226. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD226 shows lower tumor expression in KICH, LUSC, BLCA, THCA and LIHC and higher tumor expression in KIRC. The KICH box plot shows higher CD226 RNA expression in normal versus tumor tissue (log2 FC = −0.547, t-test p < 0.001).
This table shows molecular features associated with CD226 in patient tissues and cancer cell lines. In patient samples, CD226 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD226 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
